Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Oral Investig ; 23(1): 361-367, 2019 Jan.
Article in English | MEDLINE | ID: mdl-29671054

ABSTRACT

OBJECTIVES: Strong expression of survivin is associated with worse survival in many different tumours, and in cell culture, a correlation between radiation resistance and survivin expression can be seen. The potential of survivin expression as a prognostic/predictive marker or therapeutic target has not been examined in head and neck squamous cell carcinomas (HNSCC) yet. MATERIAL AND METHODS: Retrospective study of 452 tissue samples and clinical data from patients with squamous cell carcinomas of the larynx/hypopharynx (LSCC), oral cavity (OSCC) and oropharynx (OPSCC) treated in the University Medical Centre Hamburg-Eppendorf between 2002 and 2006. The expression patterns were detected by tissue microarray technique and correlated with clinical parameters (sex, age, tumour location, TNM 7th edition, grading, recurrence-free and overall survival). RESULTS: 222 OSCC, 126 OPSCC and 105 LSCC tumours of 118 females and 335 males with a mean follow-up of 41.3 months were examined. Survivin expression correlates with pN, cM, pT and overall survival. CONCLUSION AND CLINICAL RELEVANCE: The potential of survivin as a prognostic/predictive marker is very high. The findings have to be confirmed in a larger cohort of HNSCC esp. in those tumours treated primarily with radio/radiochemotherapy.


Subject(s)
Biomarkers, Tumor/metabolism , Squamous Cell Carcinoma of Head and Neck/metabolism , Survivin/metabolism , Female , Humans , Male , Neoplasm Grading , Predictive Value of Tests , Prognosis , Retrospective Studies , Squamous Cell Carcinoma of Head and Neck/mortality , Squamous Cell Carcinoma of Head and Neck/pathology , Squamous Cell Carcinoma of Head and Neck/therapy , Survival Rate , Tissue Array Analysis , Treatment Outcome
2.
Clin Oral Investig ; 23(8): 3319-3329, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30498981

ABSTRACT

OBJECTIVES: Nucleotide excision repair protein expression has been claimed to be responsible for platinum-based chemotherapy resistance. ERCC1, XPF and XPA, core proteins in DNA repair, were evaluated regarding their prognostic value in patients with head and neck squamous cell carcinoma by looking at overall survival and time to recurrence. MATERIALS AND METHODS: Tissue microarrays were constructed from 453 cases of HNSCC, including 222 oral (49%), 126 oropharyngeal (27.8%) and 105 laryngeal (23.2%) tumours. There were 284 XPF, 293 XPA and 294 ERCC1 specimens evaluable for protein expression analysis after immunohistochemical workup. Expression levels were dichotomised into high- and low-expressing groups. Outcomes for overall survival (OS) and time to recurrence (TTR) were analysed using the Kaplan-Meier method. RESULTS: No correlation between ERCC1, XPA and XPF expression and OS was found by looking at the overall patient cohort. However, subsite analysis revealed that high ERCC1 expression was associated with a significantly inferior OS in patients with SCC of the oral cavity (p = 0.028) and showed an independent predictive value in multivariate analysis (p = 0.0123). High XPA expression showed a significantly increased OS in patients with oropharyngeal SCC (p = 0.0386). Regarding XPF, no impact on OS in any subsite could be shown. CONCLUSIONS: While high ERCC1 expression functions as a predictive marker with decreased OS in patients with squamous cell carcinoma of the oral cavity, high XPA expression shows an inverse effect in the subsite of the oropharynx, which has not been described previously. CLINICAL RELEVANCE: ERCC1 and XPA might be candidates to overcome chemotherapy resistance in subtypes of HNSCC.


Subject(s)
DNA Repair , Endonucleases , Squamous Cell Carcinoma of Head and Neck , Biomarkers, Tumor , DNA-Binding Proteins/metabolism , Endonucleases/metabolism , Female , Humans , Male , Neoplasm Recurrence, Local , Prognosis , Squamous Cell Carcinoma of Head and Neck/metabolism , Xeroderma Pigmentosum Group A Protein/metabolism
3.
Rhinology ; 53(1): 54-8, 2015 03.
Article in English | MEDLINE | ID: mdl-25756079

ABSTRACT

BACKGROUND: Quality of life measurements in septorhinoplasty patients so far have taken place only to a small extent. The aim of the present study was a prospective measurement of disease-specific quality of life with a newly developed and validated instrument, the Functional Rhinoplasty Outcome Inventory 17 (FROI-17). METHODS: The patients completed the FROI-17 and the Rhinoplasty Outcome Evaluation (ROE) as disease-specific instruments preoperatively as well as 12 months postoperatively. As a general instrument, the Short Form 36 Health Survey (SF-36) was used. Furthermore, additional general questions were answered at both time points. RESULTS: Out of the 103 patients, 69 patients (32 men, 37 women) responded after 12 months (response rate 67%). Thirteen patients (18%) were not satisfied with the result of surgery. However, all scales of FROI-17 and also ROE showed a significant postoperative improvement of subjective assessments by the patients. In the SF-36, this was true in 2 out of 8 scales (mental health and role-functioning physical). Furthermore, we found significant correlations between the FROI-17 and the SF-36 scales but not between the ROE and the SF-36 scales. CONCLUSION: The disease-specific quality of life was significantly improved by septorhinoplasty. FROI-17 scales detect more functional aspects compared with the ROE thus establishing significant correlations with general quality of life measured by SF-36. The application of both FROI-17 and ROE in future clinical trials in septorhinoplasty patients is recommended.


Subject(s)
Outcome Assessment, Health Care , Quality of Life , Rhinoplasty , Adult , Female , Germany , Humans , Male , Nasal Septum/surgery , Patient Satisfaction , Prospective Studies , Surveys and Questionnaires
4.
Development ; 141(4): 773-83, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24496615

ABSTRACT

The activation of epidermal growth factor receptor (EGFR) affects multiple aspects of neural precursor behaviour, including proliferation and migration. Telencephalic precursors acquire EGF responsiveness and upregulate EGFR expression at late stages of development. The events regulating this process and its significance are still unclear. We here show that in the developing and postnatal hippocampus (HP), growth/differentiation factor (GDF) 15 and EGFR are co-expressed in primitive precursors as well as in more differentiated cells. We also provide evidence that GDF15 promotes responsiveness to EGF and EGFR expression in hippocampal precursors through a mechanism that requires active CXC chemokine receptor (CXCR) 4. Besides EGFR expression, GDF15 ablation also leads to decreased proliferation and migration. In particular, lack of GDF15 impairs both processes in the cornu ammonis (CA) 1 and only proliferation in the dentate gyrus (DG). Importantly, migration and proliferation in the mutant HP were altered only perinatally, when EGFR expression was also affected. These data suggest that GDF15 regulates migration and proliferation by promoting EGFR signalling in the perinatal HP and represent a first description of a functional role for GDF15 in the developing telencephalon.


Subject(s)
Animals, Newborn , Cell Movement/physiology , ErbB Receptors/metabolism , Gene Expression Regulation, Developmental/physiology , Growth Differentiation Factor 15/metabolism , Hippocampus/growth & development , Signal Transduction/physiology , Analysis of Variance , Animals , Bromodeoxyuridine , Carbocyanines , Cell Proliferation , Flow Cytometry , Fluorescence , Gene Expression Regulation, Developmental/genetics , Hippocampus/metabolism , Immunohistochemistry , Mice , Real-Time Polymerase Chain Reaction , Receptors, CXCR4/metabolism , beta-Galactosidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...